TD Cowen analyst Tyler Van Buren maintained a Buy rating on Gilead Sciences (GILD – Research Report) today and set a price target of ...

Gilead Sciences (GILD) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Over ...

help with community-science projects and find other ways to speak to people face-to-face. “There is an important opportunity ...

Gilead (GILD) reported positive results from a pivotal Phase 3 study of its twice-yearly HIV prevention treatment lenacapavir ...

Gilead Sciences, Inc. today presented the first in-depth look at full results from its pivotal Phase 3 PURPOSE 2 trial (NCT04925752), which is studying twice-yearly lenacapavir, the company's ...

This is the basis for specialized, AI-powered science search engines such as Consensus and Elicit. Most companies do not ...

Gilead Sciences, Inc. today announced the presentation of new research data from its innovative HIV treatment portfolio and pipeline, including a broad range of data on investigational and marketed ...

Jennifer Doudna, the co-developer of CRISPR, says there’s a “coming revolution” in climate-adapted crops and animals.

Professor Dietrich’s work has appeared in the Nature, American Political Science Review, Journal of Politics, Political Analysis, and Political Psychology. This work has also received grant support ...

UK High Court judge unconvinced by Pfizer that uniQure’s patent is invalid | Companies in dispute over patents covering ...

The EU regulator has started its review of a second CAR-T from Gilead Sciences’ Kite Pharma subsidiary, setting up a possible approval before year-end. Like Kite’s already-approved CAR-T ...

Here is set in one location — a piece of land in Pennsylvania — and seen through the perspective of a fixed camera over the course of more than 100 years. The relentless passage of time and ...